Incidence of severe adverse events in cancer patients after treatment with immune-checkpoint inhibitors during the COVID- 19 pandemic. - Kimura S; Katsuya H; Nakashima C; Sueoka-Aragane N; Hayashida K; Sasaki K; Sogawa R; Furuno T; Yamauchi M; Sugiyama Y; Noshiro H; Esaki M; et al. (BMC immunology, 2025)